| 2026-08-17 | Press release | Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update |
| 2026-06-16 | Press release | Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing |
| 2026-06-12 | Presentation | PDF icon |
| 2026-06-11 | Press release | Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing |
| 2026-06-11 | Press release | Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing |
| 2026-05-11 | Press release | Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update |
| 2026-04-29 | Press release | Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market E |
| 2026-04-27 | Press release | Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 |
| 2026-04-22 | Press release | Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Regi |
| 2026-03-24 | Press release | Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Thera |
| 2026-03-06 | Press release | Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update |
| 2026-03-03 | Press release | Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticip |
| 2026-02-25 | Presentation | PDF icon |
| 2026-02-24 | Press release | Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement |
| 2026-02-23 | Press release | Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One |
| 2026-02-17 | Press release | Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference |
| 2026-02-04 | Press release | Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Stren |
| 2026-02-03 | Press release | Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement |
| 2026-01-14 | Press release | Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP |
| 2025-11-26 | Press release | Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds |
| 2025-10-09 | Press release | Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution |
| 2025-10-09 | Press release | Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution |
| 2025-09-16 | Press release | Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for A |
| 2025-09-03 | Press release | Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rul |
| 2025-08-06 | Press release | Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting |
| 2025-07-16 | Press release | Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement |
| 2025-06-25 | Press release | Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for |
| 2025-06-25 | Press release | Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for |
| 2025-06-17 | Press release | Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering |
| 2025-06-16 | Press release | Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting |
| 2025-06-11 | Press release | Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04 |
| 2025-05-13 | Press release | Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study |
| 2025-05-08 | Press release | Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration |
| 2025-05-02 | Press release | Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds |
| 2025-03-04 | Press release | Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update |
| 2025-01-29 | Press release | Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the |
| 2024-11-14 | Press release | Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatm |
| 2024-11-13 | Press release | Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update |
| 2024-11-05 | Press release | Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer |
| 2024-09-19 | Press release | Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorde |